A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults

NCT07231978 | Completed Phase 1 FDA Drug

• 1 other identifier: A0281007
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

Prazosin hydrochloride (HCl) is a medicine taken by mouth that helps lower high blood pressure. It's used to treat hypertension, as well as heart failure. The purpose of this clinical trial is to prove that the prazosin HCl capsules made at the manufacturing site at Barceloneta (Puerto Rico) work the same in the body, as those made at Ascoli (Italy). This will be done by understanding how the different capsules and doses of prazosin HCL are changed and eliminated from your body after you take them. The study will also check how safe these capsules are and how well people can handle them. This study is seeking participants ≥ 18 years old, who are healthy and have a total body weight \>50 kg (110 lb). Before starting, participants will be interviewed and examined by skilled personnel to make sure they qualify. This will happen up to 28 days before the first dose of the study drug. Those who are eligible will check into the clinical research unit (CRU) the day before first dose of the study drug and stay there until 24 hours after their last dose \[for approximately 9 days and 8 nights for cohort (group) 1 and 5 days and 4 nights for cohort (group) 2\]. While in CRU each participant will receive by mouth either 4 capsules (cohort 1) or 2 capsules (cohort 2) of prazosin HCL at different time points. The capsules will be taken with a glass of water after overnight fasting. No food is allowed until 4 hours after taking the dose. Water is allowed freely except for 1 hour before dosing and can be consumed again 1 hour after dosing. Blood samples will be taken from participants right before they take the medicine and again after they have taken it. Electrocardiogram and blood pressure will be closely monitored. We will compare the experiences of people receiving capsules manufactured at Barceloneta to those manufactured at Ascoli. This will help us determine if capsules from Barceloneta and Ascoli are safe and effective. After completing all tests, participants will leave the CRU. Then, about 28 to 35 days after their final dose, they'll receive a follow-up phone call to check on their health. The total duration of participation from the initial ("screening") visit to discharge from the CRU will be approximately 5 weeks and from the initial visit to follow up phone call will be approximately 10 weeks.

Conditions

Healthy

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics: Area under the plasma concentration (AUC) of prazosin

  Predose, upto 5 weeks

• PK: Maximum plasma concentration (Cmax) of prazosin

  Predose, upto 5 weeks

Secondary Outcomes (5)

• Number of Participants with Treatment Emergent Adverse Events (TEAEs)

  Through study completion, approximately 10 weeks

• Number of Participants With Clinical Laboratory Abnormalities

  Through study completion, approximately 10 weeks

• Number of participants with change from baseline in physical examinations

  Through study completion, approximately 10 weeks

• Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Parameters

  Through study completion, approximately 10 weeks

• Number of Participants With Abnormalities in Vital Signs

  Through study completion, approximately 10 weeks

Study Arms (2)

Cohort 1

EXPERIMENTAL

Participants will receive a single dose of Prazosin HCl in 4 treatments.

Drug: Prazosin HCl

Cohort 2

EXPERIMENTAL

Participants will receive a single dose of Prazosin HCl in 2 treatments.

Drug: Prazosin HCl

Interventions

Prazosin HCl DRUG

Administered Orally; available in capsule form

Also known as: CP-012299

Cohort 1; Cohort 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male and female participants, 18 years of age or older and who are overtly healthy as determined by medical evaluation
• Willing to comply with all study procedures
• BMI of 16-32 kg/m2; and a total body weight \>50 kg (110 lb)
• Capable of giving signed informed consent

You may not qualify if:

• Evidence or history of clinically significant disease
• Evidence of any active suicidal ideation in the past year or suicidal behavior in the past 5 years
• Use of drugs within 14 days or 5 half-lives (whichever is longer) prior to study intervention
• Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention

Sponsors & Collaborators

• Pfizer: lead

Study Sites (1)

Pfizer Clinical Research Unit - Brussels

Brussels, Bruxelles-capitale, Région de, B-1070, Belgium

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Interventions

Prazosin

Intervention Hierarchy (Ancestors)

Quinazolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 13, 2025
• First Posted: November 17, 2025
• Study Start: November 14, 2025
• Primary Completion: April 3, 2026
• Study Completion: April 30, 2026
• Last Updated: May 14, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)